Determinants of interferon β efficacy in patients with multiple sclerosis

Clinical Effect of Neutralizing Antibodies to Interferon Beta That Persist Long After Cessation of Therapy for Multiple Sclerosis

(2010) Laura F. van der Voort   ARCHIVES OF NEUROLOGY

Transfer of myxovirus-protein-A mRNA assay for interferon-β bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience

(2010) Cinzia Zanotti et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Imaging biomarkers in multiple sclerosis

(2010) M. Filippi et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

(2010) Chris H Polman et al.   LANCET NEUROLOGY

T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis

(2010) Robert C Axtell et al.   NATURE MEDICINE

Breakthrough disease during interferon-  therapy in MS: No signs of impaired biologic response

(2010) D. Hesse et al.   NEUROLOGY

Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS

(2010) L. F. van der Voort et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

IFN-β pharmacogenomics in multiple sclerosis

(2010) Koen Vandenbroeck et al.   PHARMACOGENOMICS

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach

(2009) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

Defining Multiple Sclerosis Treatment Response With Magnetic Resonance Imaging

(2009) Paul S. Giacomini   ARCHIVES OF NEUROLOGY

Genome-wide Scan of 500 000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis

(2009) Manuel Comabella et al.   ARCHIVES OF NEUROLOGY

A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis

(2009) M. Comabella et al.   BRAIN

Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta

(2009) Giancarlo Comi   CLINICAL THERAPEUTICS

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

(2009) L. Prosperini et al.   EUROPEAN JOURNAL OF NEUROLOGY

Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis

(2009) L. F. van der Voort et al.   EUROPEAN JOURNAL OF NEUROLOGY

Antibodies against interferon-beta in multiple sclerosis

(2009) Nina Karin Aarskog et al.   JOURNAL OF NEUROIMMUNOLOGY

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

(2009) Richard A Rudick et al.   LANCET NEUROLOGY

Glypican 5 is an interferon-beta response gene: a replication study

(2009) MDC Cénit et al.   Multiple Sclerosis Journal

Measures in the first year of therapy predict the response to interferon β in MS

(2009) J Río et al.   Multiple Sclerosis Journal

Review: Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode

(2009) DS Goodin et al.   Multiple Sclerosis Journal

Predicting responders to therapies for multiple sclerosis

(2009) Jordi Río et al.   Nature Reviews Neurology

Absence of MxA induction by interferon   in patients with MS reflects complete loss of bioactivity

(2009) D. Hesse et al.   NEUROLOGY

Multiple sclerosis pharmacogenomics: Maximizing efficacy of therapy

(2009) D. J. Pappas et al.   NEUROLOGY

Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study

(2009) A. R. Pachner et al.   NEUROLOGY

Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis

(2008) Esther Byun et al.   ARCHIVES OF NEUROLOGY

Heterogeneity in Response to Interferon Beta in Patients With Multiple Sclerosis

(2008) Annie W. Chiu   ARCHIVES OF NEUROLOGY

Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients

(2008) Bianca Weinstock-Guttman et al.   JOURNAL OF NEUROIMMUNOLOGY

Interferon-β bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice

(2008) LF van der Voort et al.   Multiple Sclerosis Journal

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

(2008) J Río et al.   Multiple Sclerosis Journal

Predictive markers for response to interferon therapy in patients with multiple sclerosis

(2008) S. Malucchi et al.   NEUROLOGY

Pharmacogenomics of IFN-β in multiple sclerosis: towards a personalized medicine approach

(2008) Saskia Vosslamber et al.   PHARMACOGENOMICS

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients

(2008) Lisa G. M. van Baarsen et al.   PLoS One

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

(2007) A Sominanda et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY